SecBot SecBot
SC 13G/A ·Filed Nov 12, 2026

CABA

Cabaletta Bio, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 19h ago SEC0001374170-26-000074
Passive stake amendment
Actionable Insight • Neutral

Monitor for any future Norges Bank 13G amendments to track stake direction. A passive sovereign fund holding below 5% has no material impact on trading or governance.

DirectionNeutral
Confidencemedium
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.33
T+0 close · Nov 12, 2026 · via day close
Latest settled
−3.76%
T+1 · $1.28
Vs SPY
−3.40%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $1.33entry
  2. T+1 · 4d ago −3.76%α −3.40% · $1.28
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Norges Bank filed an amended Schedule 13G for Cabaletta Bio, reporting beneficial ownership of 8,663,310 shares (4.019% of common stock) as of September 30, 2026. This is a routine passive stake update by a sovereign wealth fund; no prior Norges Bank 13G for CABA is in the provided context for comparison, so the direction of change is unknown.

Key Financial Metrics

Stake
4.019%
Investor
Norges Bank
Investor Type
sovereign

Key Facts

  • Norges Bank reported 8,663,310 shares of Cabaletta Bio common stock as of September 30, 2026
  • Stake represents 4.019% of outstanding shares
  • Filing is an amendment to Schedule 13G, indicating passive investment intent
  • No prior Norges Bank 13G for CABA is in the provided context for comparison

Financial Impact

Stake valued at approximately $13.0M based on $1.50/share market price at analysis time ($324M market cap / 216M shares outstanding)

ownership_percentage

Risk Factors

  • No prior filing for comparison, so direction of change is unknown
  • Stake is below 5%, reducing disclosure and influence requirements

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001374170-26-000074
Document: 0001374170-26-000074-index.html0001374170-26-000074
Document: 0001374170-26-000074.txt0001374170-26-000074

Track record

29 reports on CABA

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Viewing Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026